Denali Therapeutics Inc.

Developing BBB-crossing biotherapeutics for lysosomal storage and neurodegenerative diseases; AVLAYAH launched in 2026.

Back to company catalog

Rare disease & neurodegeneration · Blood-brain-barrier TransportVehicle biologics · Commercial + clinical

Compare report options